What Researchers Did
The authors searched medical databases for randomised controlled trials of any treatment for bisphosphonate-related osteonecrosis of the jaw (BRONJ), a rare but serious bone problem in the jaw linked to bisphosphonate drugs.
What They Found
This Cochrane review found only one small trial at high risk of bias, and it could not confirm or refute whether hyperbaric oxygen therapy (HBOT) helps people with BRONJ. The trial randomised 49 participants, most of whom had cancer, to standard care (surgery, antibiotics and oral rinses) or standard care plus HBOT at 2 atmospheres twice a day for 40 treatments. At three months, the HBOT group was more likely to have improvement (risk ratio 1.94, 95% confidence interval 1.01 to 3.74), but there was no clear difference in the outcome "healed" (risk ratio 3.60, 95% confidence interval 0.87 to 14.82). There was no clear difference in improvement or healing at six, 12 and 18 months or last contact, and the trial gave no information on adverse events.
What This Means for Canadian Patients
For people with BRONJ, the review found a lack of randomised trial evidence to guide any treatment. The one HBOT trial could not confirm or refute that HBOT works, and the evidence quality was rated very low. Patients should discuss treatment options with their oral-maxillofacial surgeon.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The only included trial was underpowered and at high risk of bias because of no blinding, cross-over of participants between groups, and very high attrition (50% at 12 months and 80% at 18 months, against a planned 24 months of follow-up).